Lipocine Inc.
LPCN evidence brief
What we can confirm
- Market Cap:
- $18.7M
What it means
What to watch
Prepared research question
What matters most for LPCN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LPCN
Lipocine Inc. is a biopharmaceutical company developing oral prodrug-based therapies for central nervous system disorders, metabolic conditions, and other indications, with a pipeline spanning postpartum depression, major depressive disorder, essential tremor, epilepsy, and obesity management.
Key risk: No approved products
Market Cap
$18.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Lipocine Inc..
Lipocine Inc. is a biopharmaceutical company developing oral prodrug-based therapies for central nervous system disorders, metabolic conditions, and other indications, with a pipeline spanning postpartum depression, major depressive disorder, essential tremor, epilepsy, and obesity management.
- Cash & equivalents of $5.0M as of 2026-06-30 [sec]
- Total revenue of $0.2M and net income of -$2.6M as of 2026-06-30 [sec]
- Shareholders' equity of $21.8M as of 2026-06-30 [sec]
- Pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2203 for essential tremor, LPCN 2101 for epilepsy, and LPCN 2401 for obesity management [sec_mda · as of 2026-08-04]
- Company expects existing capital to fund operations through at least August 4, 2027, but will need additional capital at some point [sec_mda · as of 2026-08-04]
What works
- Pipeline targets large, underserved CNS and metabolic indications with multiple clinical-stage candidates [sec_mda · as of 2026-08-04]
- LPCN 1154 for postpartum depression has potential advantages including rapid relief and oral convenience, and a Phase 3 study is planned [sec_mda · as of 2026-05-07] [catalyst]
- Company has out-licensing partnerships for TLANDO in certain territories, providing non-dilutive revenue potential [sec_mda · as of 2026-08-04]
- Cash runway projected through at least August 2027, giving time to advance key programs [sec_mda · as of 2026-08-04]
What to weigh
- No approved products; all revenue is from partnerships, with total revenue of only $0.2M as of 2026-06-30 [sec]
- Net loss of $2.6M as of 2026-06-30 indicates ongoing cash burn [sec]
- Company acknowledges it will need to raise additional capital to continue operations beyond current runway [sec_mda · as of 2026-08-04]
- Multiple pipeline candidates are in early stages (Phase 2 or pre-Phase 2) with no guarantee of clinical or regulatory success [sec_mda · as of 2026-08-04]
From the filings
Quoted directly from source documents.
Company expects capital to last through at least August 4, 2027
“We believe that our existing capital resources, together with interest thereon, will be sufficient to meet our projected operating requirements through at least August 4, 2027”
SEC MD&A · August 4, 2026
Company will need to raise additional capital
“we will need to raise additional capital at some point”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2026-09-01 · Phase 3 start for LPCN 1154 in postpartum depression — A randomized, blinded, placebo-controlled study to evaluate safety and efficacy of oral LPCN 1154A in women with postpartum depression.
Risks & what to watch (4)›
Key risks
- No approved products — All revenue is from partnerships; no product has received regulatory approval [sec]
- Cash burn and need for capital — Net loss of $2.6M as of 2026-06-30; company acknowledges need for additional capital [sec] [sec_mda · as of 2026-08-04]
- Clinical-stage pipeline uncertainty — Multiple candidates are in early development; clinical and regulatory success is not guaranteed [sec_mda · as of 2026-08-04]
- Dependence on partnerships — Out-licensing and partnership revenues are uncertain and may not materialize as expected [sec_mda · as of 2026-08-04]
What to watch
- Initiation and results of Phase 3 study for LPCN 1154 in postpartum depression, expected to start around September 2026 [catalyst]
- Ability to secure additional capital or partnerships to extend cash runway beyond August 2027 [sec_mda · as of 2026-08-04]
- Progress of early-stage CNS candidates (LPCN 2201, LPCN 2203, LPCN 2101) into Phase 2 studies [sec_mda · as of 2026-08-04]
- Out-licensing deals for TLANDO and other partnered assets outside currently licensed territories [sec_mda · as of 2026-08-04]
Sources: Catalysts · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Lipocine Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lipocine Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$26.2M
| Holder | Shares | Value |
|---|---|---|
| ikarian capital, llc | 508,556 | $4.1M |
| squadron capital management llc | 450,000 | $3.6M |
| stempoint capital lp | 320,840 | $2.6M |
| eversept partners, lp | 294,989 | $2.4M |
| rosalind advisors, inc. | 221,616 | $1.8M |
| vanguard capital management llc | 200,668 | $1.6M |
| aigh capital management llc | 200,000 | $1.6M |
| boothbay fund management, llc | 140,487 | $1.1M |
| seven fleet capital management lp | 124,942 | $998K |
| birchview capital, lp | 111,786 | $893K |
Showing top 10 of 47 institutional holders of Lipocine Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 2.0%
- Days to cover
- 1.4
- Shares short
- 143,656
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LPCN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lipocine Inc.?
Lipocine Inc. is a biopharmaceutical company developing oral prodrug-based therapies for central nervous system disorders, metabolic conditions, and other indications, with a pipeline spanning postpartum depression, major depressive disorder, essential tremor, epilepsy, and obesity management.
Who is the CEO of Lipocine Inc.?
Dr. Mahesh V. Patel Ph.D. is the chief executive officer of Lipocine Inc. (LPCN).
Where is Lipocine Inc. headquartered?
Lipocine Inc. (LPCN) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does Lipocine Inc. focus on?
Lipocine Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.